bispecific antibodies

horse horse riding lasso man on horse in shadows
Biotech

Ollin hauls in $330M for Vabysmo challenger's ph. 3 gauntlet

Two trials will focus on the lead indication of diabetic macular edema, where OLN324 topped Vabysmo in an earlier phase 1b trial.
Darren Incorvaia Jun 24, 2026 7:00am
more expensive

Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact

Jun 3, 2026 9:48am
ASCO
Favicon Fierce Pharma

At ASCO, China biotech industry cements its coming of age

Jun 3, 2026 8:50am
ASCO
Favicon Fierce Pharma

Akeso's 34% overall survival win comes with caveats

May 31, 2026 8:00am
Graphic of a fork in the road with arrows pointing in either direction

ASCO: BioNTech/BMS, Pfizer split on bispecific approach in NSCLC

May 30, 2026 3:30pm
lung
Favicon Fierce Pharma

ASCO: Merck, Kelun's sac-TMT combo beats Keytruda by 65% on PFS

May 21, 2026 5:00pm